Genetic obesity such as Prader–Willi syndrome (PWS) is a multifaceted condition influenced by various elements, including genetic predisposition, environmental factors, and behavioral components. This meta-analysis explored the reported efficacy of therapeutics in clinical trials for PWS by evaluating clinical endpoints reached in the course of the study and the adverse events observed for each. We looked at glucagon-like peptide 1 (GLP1) receptor-mediated and non-GLP1 receptor-mediated therapies and compared their performance in study arms across time and standard of care (SoC). In addition, we estimated the present market shares across different obesity and diabetes assets which have been tested against PWS. In conclusion, the study points to two key readouts. First, existing obesity and diabetes assets are not effective for genetic obesity such as PWS. The unmet needs remain high. Second, the markets for obesity and diabetes are in a stage of expansion. A collaborative approach to therapy development for genetic obesity is required to improve the quality of life for affected individuals.

Clinical Efficacy Landscaping in Genetic Obesity: A Meta-analysis in Prader–Willi Syndrome (PWS)